Speaking during a meeting of the Kentucky Equine Drug Research Council Sept. 11, representatives of the regenerative medicine company ReCellerate pitched the council for a clinical trial of the company’s Equiflow stem cell-derived treatment.
Speaking during a meeting of the Kentucky Equine Drug Research Council Sept. 11, representatives of the regenerative medicine company ReCellerate pitched the council for a clinical trial of the company’s Equiflow stem cell-derived treatment.